- Home
- ALV vs IBRX Comparison
ALV vs IBRX Comparison
Compare ALV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | IBRX |
|---|---|---|
| Founded | 1953 | 2014 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.5B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALV | IBRX |
|---|---|---|
| Price | $121.13 | $7.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $134.00 | $12.57 |
| AVG Volume (30 Days) | 729.9K | ★ 8.8M |
| Earning Date | 04-17-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 18.78 | ★ 38.71 |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $10,815,000,000.00 | $113,288,000.00 |
| Revenue This Year | $2.10 | $88.59 |
| Revenue Next Year | $3.47 | $131.15 |
| P/E Ratio | $37.77 | ★ N/A |
| Revenue Growth | 4.09 | ★ 668.31 |
| 52 Week Low | $99.16 | $1.95 |
| 52 Week High | $132.17 | $12.43 |
Technical Indicators
Market Signals| Indicator | ALV | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 53.72 |
| Support Level | $113.89 | $6.68 |
| Resistance Level | $124.61 | $8.46 |
| Average True Range (ATR) | 2.82 | 0.38 |
| MACD | -0.07 | 0.07 |
| Stochastic Oscillator | 47.33 | 92.74 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.